Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection
- Yuanming Pan†1,
- Jiaqiang Huang†2,
- Rui Xing1,
- Xin Yin1,
- Jiantao Cui1,
- Wenmei Li1,
- Jun Yu3 and
- Youyong Lu1Email author
© Pan et al.; licensee BioMed Central Ltd. 2013
Received: 17 March 2013
Accepted: 10 July 2013
Published: 19 July 2013
Metallothionein 2A (MT2A) as a stress protein, plays a protective role in gastric mucosal barrier. Its role in the development of gastric cancer (GC) is unclear. The mechanism of MT2A will be investigated in gastric tumorigenesis.
MT2A expression was detected in 973 gastric specimens. The biological function was determined through ectopic expressing MT2A in vitro and in vivo. The possible downstream effectors of MT2A were investigated in NF-κB signaling. The protein levels of MT2A, IκB-α and p-IκB-α (ser32/36) expression were analyzed in a subset of 258 patients by IHC staining. The prognostic effects of MT2A, status of IκB-α and TNM stage were evaluated using the Kaplan-Meier method and compared using the log-rank test.
Decreased MT2A expression was detected in cell lines and primary tumors of GC. In clinical data, loss of MT2A (MT2A + in Normal (n =171, 76.0%); Intestinal metaplasia (n = 118, 50.8%); GC (n = 684. 22.4%, P < 0.001)) was associated with poor prognosis (P < 0.001), advanced TNM stage (P = 0.05), and down-regulation of IκB-α expression (P < 0.001). Furthermore, MT2A was the independent prognostic signature segregated from the status of IκB-α and pathological features. In addition, MT2A inhibited cell growth through apoptosis and G2/M arrest, which negatively regulated NF-κB pathway through up-regulation of IκB-α and down-regulation of p-IκB-α and cyclin D1 expression.
MT2A might play a tumor suppressive activity through inhibiting NF-κB signaling and may be a prognostic biomarker and potential target for individual therapy of GC patients.
KeywordsMetallothionein 2A NF-κB signaling Gastric cancer Prognosis TNM stage
Abundance of Metallothionein 2A (MT2A) exhibits in the gastric mucosal barrier, but its role in the progression of gastric cancer (GC) is still unclear. In this analysis of 171 normal gastric tissues, 118 intestinal metaplasia, and 684 primary gastric cancers, decreased MT2A was significantly correlated with poor prognosis. It inhibited the proliferation of GC cells through NF-κB signaling inactivation. These results indicate that MT2A may be an important prognostic marker and therapeutic target for GC.
Gastric cancer (GC) is the most commonly diagnosed malignancy and remains a significant burden of cancer in Asia, especially in China[1, 2]. Most GC patients undergoing surgery are already at an advanced stage and the 5-year survival is varied. Several histological factors have been reported to be prognostic factors of GC, including tumor size, WHO classification, tumor-node-metastasis (TNM) stage system, and differentiation grade[3, 4]. However, prognosis of GC patients at the same stage is still inconsistent. Therefore, identification of specific diagnostic markers and therapeutic target would allow reliable prediction, effective extension of postoperative survival and life quality of patients.
Cellular stress has been shown to play a role in the molecular regulation of carcinogenesis[7, 8]. Metallothioneins (MTs) as the stress proteins with low molecular weight and rich-cysteine have the ability of a high affinity for metal ions and ROS scavengers. MT2A as the main isoform of MTs plays an important role in gastric mucosal barrier in patients with gastritis and rodent models[9, 10]. Pre-administration of exogenous MT2A or pre-induction of endogenous MT2A can protect stomach and liver against stress-induced damage and inhibit the formation of stress-induced lipid peroxide, implying a protective effect of MT2A on stress-induced pathogenesis and a potential therapeutic target applied for early prevention–. Recently, MT2A plays an important role in tumorigenesis and progression of multiple carcinomas including GC. The mice loss of MT2A gene predisposed to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-κB target genes, which demonstrates that MT2A protects mice from hepatocarcinogen-induced liver damage and carcinogenesis, underscoring its potential therapeutic application against hepatocellular cancer. Some studies focused on the role of MT2A in the protection against H.pylori-induced gastric injury using MT-null mice. Himeno, S. discovered that activation of NF-κB and expression of NF-κB-mediated chemokines in gastric cells were markedly higher in MT2A-null mice than in wide-type mice. These data imply that MT2A realizes negative control of the transcription factor NF-κB activity, but its role in gastric carcinogenesis is still ambiguous–.
Aberrant activation of NF-κB is associated with cell inflammation, malignancy, and tumor progression[7, 19]. The functional activity of NF-κB is inhibited through binding to its inhibitor, IκB-α. Activation of NF-κB is resulted from proteasome-mediated degradation of IκB-α by phosphorylation of the inhibitor (p-IκB-α), which suggests that NF-κB pathway is a potential target for individual therapy–.
Some evidence indicated that increased MT2A expression is important for cancer progression, and MT2A is initially proposed as a proto-oncogene in breast, esophageal, prostate, and ovarian cancers, associated with malignancy and poor prognosis–. In contrast, it is down-regulated in gastrointestinal tumors and hepatocellular carcinomas, where MT2A is either inversely correlated or unrelated to mortality[28, 29]. However, the variation of MT2A and its clinical evaluation remains contradictory in GC[28, 30, 31]. These results suggest that dysregulation of MT2A is involved in tumor pathogenesis, although the exact role is still unclear in GC.
Hence, we focused to reveal the co-expression of MT2A and IκB-α gene correlated with clinical pathological features and outcomes in a large scale of gastric tumors with long-term follow-up data. Furthermore, we systematically analyzed the role of MT2A as a stress protein and negative regulator in NF-κB activation to characterize its biological role and molecular mechanism in vitro and in vivo.
Logistic regression analysis of clinicopathological features and prognosis in GC
No. of cases (n = 258)
Survival time (month)
66.4 ± 4.6
54.1 ± 4.8
Age at diagnosis
65.0 ± 4.9
59.2 ± 5.6
105.5 ± 7.7
I vs. IV
74.0 ± 5.9
II vs. IV
49.1 ± 3.4
III vs. IV
35.8 ± 4.1
87.2 ± 9.9
pT1 vs. pT4
89.1 ± 9.1
pT2 vs. pT4
49.1 ± 2.9
pT3 vs. pT4
40.1 ± 5.3
Lymph node status
89.8 ± 6.2
pN0 vs. pN3
50.5 ± 3.4
pN1 vs. pN3
46.6 ± 6.0
pN2 vs. pN3
47.5 ± 12.6
67.5 ± 4.3
27.6 ± 5.8
Degree of differentiation
76.0 ± 6.0
59.8 ± 4.4
53.9 ± 3.4
86.9 ± 9.2
61.6 ± 4.9
64.9 ± 5.1
74.1 ± 5.3
47.7 ± 3.4
IHC staining in tissue array was performed with MT2A antibody (1:100 dilution; 18-0133, Invitrogen, CA, US), p-IκB-α antibody (1:200 dilution; ab47752, Abcam, Cambridge, UK), IκB-α antibody (1:300 dilution; sc-371, Santa Cruz Biotechnology, CA). For each biomarker, images were scored visually by three pathologists who were blinded to clinical outcome. Discrepancies were resolved by consensus. Scores were assigned as a percentage of positive staining within each cylinder. The mean percentage value of the two cores was calculated to represent one tumor (Additional file1).
Gastric cancer cell lines BGC823, MGC803, SGC7901 and PAMC82 were established in China and purchased from the tissue bank of Shanghai (Shanghai, China). Especially, BGC823 cells exhibited high tumorigenecity. MKN45, AGS, N87, RF-1, RF-48, SNU-1, SNU-5 and SNU-16 cell lines were purchased from ATCC (American Type Culture Collection, Manassas, US). GES-1, an immortalized human gastric epithelial cell line, was generated by SV40 viral transfection at Beijing Cancer Hospital and cultured in DMEM medium supplemented with 10% fetal bovine serum (Gibco, Life technologies, Grand Island, NY, USA) at 37°C in a humidified atmosphere containing 5% CO2.
MTT and soft agar assay
The cells were seeded into 96-well culture plates, and MTT was added to the cells at 1-5 days. MTT (5 μg/ml) was removed after 4 h incubation, and then dimethyl sulfoxide (DMSO) was added to solubilize the formazan product. The absorbency at 490 nm/570 nm was assayed by a microplate reader (Bio-rad680 ELISA). Cells were then incubated for 4 weeks, stained with vital tetrazolium dye INT (piodonitrotetrazolium, Invitrogen) to document the presence or absence of viable cell colonies. The soft agar was fixed with 100 μl methanol-acetic acid (3:1 vol/vol) and colonies were counted.
BGC823 cells (5 × 105 cells suspended in 0.1 ml PBS) transfected with MT2A over-expressed vector or empty vector were injected subcutaneously into the dorsal flank of five 4-week-old female Balb/C nude mice (MT2A-expression clones on the right and vector control clones on the left. Tumor diameter was measured and documented every 5 days. Tumor volume was calculated according to the formula ab2/2 (a > b). At the end of 25 days, all mice were sacrificed and the tumor volume was measured. Three independent experiments were performed and gave the similar results. The animals were maintained in facilities approved by the association for assessment and accreditation of Laboratory Animal Care in accordance with the current regulations and international standards.
χ2 test statistics and Student’s t-test were used to compare pretreatment characteristics of patient cases. The cancer-related survival was analyzed using the Kaplan–Meier method and compared using log-rank tests. The Spearman rank test and Fisher’s exact test were applied to demonstrate clinicopathological correlations. A Cox proportional hazard regression model was used with associated 95% confidence intervals (CIs) and P values. All statistical tests were two-sided, and P values of less than 0.05 were considered statistically significant. The statistical analysis was performed using the statistical package SPSS (Version 16.0; SPSS Inc, Chicago, IL).
All animal studies were approved by the Ethics Committee of Peking University Cancer Hospital. The use of human tissues and clinical data was according to the guidelines of the hospital and approved by the Local Ethical Committee.
Decreased MT2A expression is a molecular event in cell lines and primary tumors of GC
36 primary tumors of GC with adjacent normal tissues were also examined in Figure 1C and D, to confirm the results derived from GC cell lines, decreased MT2A mRNA was displayed in GCs compared with that in matched normal controls (27/36, 75.0%, P < 0.001, Figure 1C). Low expression of MT2A protein was detected in 29 out of 36 GC cases (80.6%) compared with the matched normal tissues (P < 0.001, Figure 1D). The mRNA level of MT2A was correlated to the protein level detected by Western blot (R = 0.510, P = 0.009). In humans, the MTs are encoded by a family of genes consisting of 10 functional MT isoforms and the encoded proteins are conventionally subdivided into four groups, MT1, MT2, MT3, and MT4 proteins. Since the coding regions of MT isoforms are highly conserved in transcript and protein levels, MT2A is highly homologous with MT1G, MT1E and MT1F (Additional file 1: Figure S1B). Hence, experiments on any individual isoform should be carefully conducted to ensure that the exact isoform is analyzed. In this study, differential expression of MT1 transcripts was observed in GC cell lines and primary tumors of GC with adjacent normal controls (n = 36) (Additional file 1: Figures S1A and S2). We authenticated actual MT2A gene down-regulation in GC significantly compared with adjacent normal tissues (27/36, 75%, Figure 1C). There was no difference of MT1E and MT1F and MT1G mRNA transcripts in normal and tumor samples as well as MT1B mRNA transcript was not detectable in all cells and tissues (Additional file 1: Figures S1A and S2).
To investigate the candidacy of MT2A in gastric tumorigenesis, we initially characterized the status of MT2A expression in 171 normal tissues, 118 IM and 684 GC samples by IHC staining. The antibody for MT2A (E9 18-0133, Invitrogen) is not specific for MT-2A only, and cross-reacts with MT-1 to some extent, even if it is cloned by the full length of MT2A. Since there is no specific antibody to detect MT2A, so we use the common commercial antibody for IHC staining which was published in most related studies, MT2A expression is classified as low and high expression in normal appearance tissues, IM, and primary GCs. High level of MT2A expression was detected in 153 of 684 (22.4%) GC cases, and 60 of 118 (50.8%) IM cases, as well as 130 of 171 (76.0%) normal appearance cases, respectively (Additional file1: Table S3, P < 0.001), it was consisted with MT2A mRNA transcripts and protein expression by Western blot. The expression of MT2A was classified as negative, weak and strong cases in 13 (7.6%), 28 (16.4%) and 130 (76.0%) out of 171 normal tissues, respectively; In IM tissues, 27 (22.9%), 31 (26.3%) and 60 (50.8%) out of 118 IM cases were detected respectively; In GC samples, 494 (72.2%), 37 (5.4%) and 153 (22.4%) out of 684 GC cases were detected respectively (Figure 1F, Additional file1). There was a gradually decreased expression of MT2A protein in IM and GC (P < 0.001, Figure 1E and F). It is clear that MT2A mRNA was highly expressed in GES1 cells and normal tissues, but was reduced or lost in most GC cells and tissues. These results suggest that decreased MT2A is a molecular event in tumorigenesis and progression.
MT2A expression is correlated with poor prognosis in GC
Cox regression analysis of clinicopathological features and molecular signatures in GC
Covariate by end point
Age ≥ 60 years
0.840 to 1.934
0.499 to 1.233
0.509 to 1.778
Tumor invasive depth
1.389 to 2.638
Lymph node status
1.034 to 1.612
1.332 to 5.056
0.187 to 0.683
0.524 to 1.311
1.256 to 2.912
Prognostic significance of MT2A combined with TNM stage in GC patients
To further elucidate MT2A expression in prognostic significance, we combined MT2A expression with the clinicopathological features in GC. The aim was to evaluate the prognosis of GC patients with pathological classification, and to investigate whether pathological classification should be further sub-classified for more accurate prediction of outcome. As shown in Additional file1: Table S4, MT2A expression in GC was associated with TNM stage and tumor differentiation, implying that MT2A may be a potential molecular biomarker to predict pathological classification in GC. As dichotomous covariates, both MT2A and TNM stage were independent predictors for survival (Table 2, Figure 2A and B). Prognostic significance of MT2A expression was further analyzed in GC patients according to the pTNM classification system. There was a significant difference in overall survival between patients with MT2A expression in both early (I and II) and advanced (III and IV) stage groups (P = 0.048 and P < 0.001, respectively; Figure 2C and D). Moreover, MT2A expression status was also effective for the prognosis in the same stages (P = 0.052, Figure 2E; P < 0.001, Figure 2F; P < 0.001, Figure 2G and P < 0.001, Figure 2H). These data represent that MT2A is a molecular signature to predict clinical outcome based on TNM stage.
Restoration of MT2A expression results in growth suppression of GC cells in vitro and in vivo
Further, we plated BGC823 cells repressing MT2A or not into soft agar, ectopic expression of MT2A was confirmed by western blot analysis first (Figure 3A). After 3 weeks of culture MT2A expression caused a statistically significant reduction in colony formation (P = 0.0053, Figure 3C). Furthermore, there was a dramatic growth inhibition of MT2A-re-expressing cells compared with the negative control (P = 0.0027, Figure 3D) in the xenograft models. These data demonstrate that MT2A might play a role in suppressing proliferation of GC cells in vitro and in vivo.
MT2A represses NF-κB activity through IκB-α up-regulation
Based on the similarity of MT isoform, the specific primer pairs for different MT isoforms were designed to illustrate whether ectopic expression of MT2A or knockdown of MT2A could affect on other MT isoforms, as shown in Additional file1: Figure S4, there was no obvious change for other MT isoforms after re-expression or knockdown of MT2A. Interestingly, different cell lines exhibited differential expression of MT isoforms. These data indicate that a significant reduction of p-IκB-α and cyclin D1 is induced by ectopic MT2A expression in GC cells, suggesting that MT2A suppressed cell proliferation and tumorigenicity through NF-κB inactivation.
IκB-α expression is correlated with MT2A in gastric tumors
Combined MT2A and IκB-α expression status as a molecular signature to predict prognosis in GC
The aberrant NF-κB activation led to poor prognosis, associated with p-IκB-α activation and degradation of IκB-α in many types of cancer. To assess MT2A and IκB-α status in GCs in more detail, further stratification was conducted according to status of IκB-α expression. p-IκB-α + patients had shorter overall survival than p-IκB-α- patients in high expression of IκB-α (IκB-α+) subgroup (n = 94, P = 0.047, Figure 6C). When combining MT2A and IκB-α expression as the co-index for the prognostic prediction in GC, the overall survival was significantly better in MT2A+/IκB-α + group (P < 0.05, Figure 6D). In most samples with MT2A-/IκB-α- (n = 142), p-IκB-α + subgroup had the worse outcome (P = 0.026, Figure 6E). Furthermore, when combing MT2A and p-IκB-α expression together, we found that only MT2A+/p-IκB-α- group had the best survival (P < 0.01; Figure 6F). These results show that combination of MT2A and p-IκB-α expression might be a molecular signature to predict prognosis of GC.
GC is histopathologically heterogeneous and difficult for prognosis prediction by tumor grade or histological type. In this study, we offered both clinical and mechanistic evidence that MT2A is an independent prognostic factor and effective molecular target for cancer therapy. MT2A has been shown to reduce the tumorigenicity in vivo and in vitro, and decrease or loss of MT2A is a critical molecular event in GC cell lines and primary GC tissues. Decreased MT2A was associated with gastric malignant transformation, as well as poor survival. Re-expressing MT2A significantly inhibited the growth of GC cells. Interestingly, restoration of MT2A led to down-regulation of p-IκB-α and cyclin D1 but to induce IκB-α up-regulation, which was consistent with the typical apoptosis of GC cells resulting from suppression of NF-κB activation, accompanied with G2/M arrest[34–36]. Moreover, cyclin D1 is a therapeutic target in cancer. Its abundance will lead to oncogenic activation in stomach[37, 38].
Differential expression of MT isoforms was detected in GC cells and tissues, which indicated that the potential role of MT isoforms in carcinogenesis gained attention and make sure that the exact isoform is analyzed in our study. It is therefore not surprising that members of the MT family may be involved pleiotropically in a number of different biological functions except for ROS scavenger and metal-binding ability. However, there are no readily available commercial antibodies for distinguishing the highly homologous protein isoforms of MT1/2. The controversial results of MT in human neoplasia could possibly be attributed to the methods applied using antibodies that were unable to distinguish specific MT1/2 isoforms. In most studies where immunohistochemistry was applied, MT expression was revealed antibodies against a common epitope of MT1 and MT2A that were unable to detect over-expression due to other MT isoforms, reducing the significance of MT participation in tumors.
In addition, MT2A suppression is frequently observed in GC, and similar data was reported in hepatocellular and colon cancer[44, 45]. Duncan et al reported that down-regulation of MT2A expression occurred upon immortalization, which implies that MT2A is down-regulated when human cells become immortal phenotypes, a key event in tumorigenesis.
Collectively, down-regulation of MT2A expression is an independent predictor for clinical outcome. It is conceivable that re-expression of MT2A can be considered as a molecular target in GC for molecular classification and individual therapy.
This study was conducted with the approval of Peking University Cancer Hospital & Institute Review Board.
Yuanming Pan and Jiaqiang Huang contributed equally to this work, and we also thank the tissue bank of Peking University Cancer Hospital & Institute for providing gastric specimens.
This work was supported by the National Bio-Tech 863 Program (No. 2012AA02A504), The National Key Basic Research Program (973 Program, No. 2004CB518708), and the Beijing Municipal Science & Technology Commission (No. D0905001040631).
- Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006, 12: 17-20.PubMed CentralPubMedGoogle Scholar
- McCracken M, Olsen M, Chen MS, Jemal A, Thun M, Cokkinides V, Deapen D, Ward E: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Canc J Clin. 2007, 57: 190-205. 10.3322/canjclin.57.4.190.View ArticleGoogle Scholar
- Mohri Y, Tanaka K, Ohi M, Yokoe T, Miki C, Kusunoki M: Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg. 2010, 34: 285-290. 10.1007/s00268-009-0302-1.View ArticlePubMedGoogle Scholar
- Kim JS, Kim MA, Oh DY, Lee SH, Kim DW, Im SA, Kim WH, Yang HK, Heo DS, Bang YJ: Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. Jpn J Clin Oncol. 2011, 41: 245-252. 10.1093/jjco/hyq215.View ArticlePubMedGoogle Scholar
- Park JC, Lee YC, Kim JH, Kim YJ, Lee SK, Hyung WJ, Noh SH, Kim CB: Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol. 2009, 99: 395-401. 10.1002/jso.21281.View ArticlePubMedGoogle Scholar
- Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y: The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One. 2011, 6: e29670-10.1371/journal.pone.0029670.PubMed CentralView ArticlePubMedGoogle Scholar
- Shibata W, Takaishi S, Muthupalani S, Pritchard DM, Whary MT, Rogers AB, Fox JG, Betz KS, Kaestner KH, Karin M, Wang TC: Conditional deletion of IkappaB-kinase-beta accelerates helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia. Gastroenterology. 2010, 138: 1022-1034. 10.1053/j.gastro.2009.11.054. e1021-1010PubMed CentralView ArticlePubMedGoogle Scholar
- Park S, Kim WS, Choi UJ, Han SU, Kim YS, Kim YB, Chung MH, Nam KT, Kim DY, Cho SW, Hahm KB: Amelioration of oxidative stress with ensuing inflammation contributes to chemoprevention of H. pylori-associated gastric carcinogenesis. Antioxid Redox Signal. 2004, 6: 549-560. 10.1089/152308604773934305.View ArticlePubMedGoogle Scholar
- Mita M, Satoh M, Shimada A, Okajima M, Azuma S, Suzuki JS, Sakabe K, Hara S, Himeno S: Metallothionein is a crucial protective factor against Helicobacter pylori-induced gastric erosive lesions in a mouse model. Am J Physiol Gastrointest Liver Physiol. 2008, 294: G877-G884. 10.1152/ajpgi.00251.2007.View ArticlePubMedGoogle Scholar
- Mitani T, Shirasaka D, Aoyama N, Miki I, Morita Y, Ikehara N, Matsumoto Y, Okuno T, Toyoda M, Miyachi H: Role of metallothionein in Helicobacter pylori-positive gastric mucosa with or without early gastric cancer and the effect on its expression after eradication therapy. J Gastroenterol Hepatol. 2008, 23: e334-e339. 10.1111/j.1440-1746.2007.05124.x.View ArticlePubMedGoogle Scholar
- Tran CD, Huynh H, van den Berg M, van der Pas M, Campbell MA, Philcox JC, Coyle P, Rofe AM, Butler RN: Helicobacter-induced gastritis in mice not expressing metallothionein-I and II. Helicobacter. 2003, 8: 533-541. 10.1046/j.1523-5378.2003.00174.x.View ArticlePubMedGoogle Scholar
- Higashimoto M, Isoyama N, Ishibashi S, Inoue M, Takiguchi M, Suzuki S, Ohnishi Y, Sato M: Tissue-dependent preventive effect of metallothionein against DNA damage in dyslipidemic mice under repeated stresses of fasting or restraint. Life Sci. 2009, 84: 569-575. 10.1016/j.lfs.2009.01.022.View ArticleGoogle Scholar
- Jiang Y, Kang YJ: Metallothionein gene therapy for chemical-induced liver fibrosis in mice. Mol Ther. 2004, 10: 1130-1139. 10.1016/j.ymthe.2004.08.011.View ArticlePubMedGoogle Scholar
- Jiang P, Chang L, Pan CS, Qi YF, Tang CS: Protective role of metallothionein in stress-induced gastric ulcer in rats. World J Gastroenterol. 2005, 11: 2739-2743.PubMed CentralView ArticlePubMedGoogle Scholar
- Majumder S, Roy S, Kaffenberger T, Wang B, Costinean S, Frankel W, Bratasz A, Kuppusamy P, Hai T, Ghoshal K, Jacob ST: Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes. Canc Res. 2010, 70: 10265-10276. 10.1158/0008-5472.CAN-10-2839.View ArticleGoogle Scholar
- Kim CH, Kim JH, Lee J, Ahn YS: Zinc-induced NF-kappaB inhibition can be modulated by changes in the intracellular metallothionein level. Toxicol Appl Pharmacol. 2003, 190: 189-196. 10.1016/S0041-008X(03)00167-4.View ArticlePubMedGoogle Scholar
- Sakurai A, Hara S, Okano N, Kondo Y, Inoue J, Imura N: Regulatory role of metallothionein in NF-kappaB activation. FEBS Lett. 1999, 455: 55-58. 10.1016/S0014-5793(99)00839-X.View ArticlePubMedGoogle Scholar
- Butcher HLKW, Collins O, Zalups RK, Koropatnick J: Metallothionein mediates the level and activity of nuclear factor kappa B in murine fibroblasts. J Pharmacol Exp Ther. 2004, 310: 589-598. 10.1124/jpet.104.066126.View ArticlePubMedGoogle Scholar
- Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870.View ArticlePubMedGoogle Scholar
- Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004, 431: 461-466. 10.1038/nature02924.View ArticlePubMedGoogle Scholar
- Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, Khavari PA: NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 2003, 421: 639-643. 10.1038/nature01283.View ArticlePubMedGoogle Scholar
- Baud VKM: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009, 8: 33-40. 10.1038/nrd2781.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee CHJY, Kim SH, Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 2007, 29: 19-35. 10.1002/biof.5520290103.View ArticlePubMedGoogle Scholar
- Jin R, Chow VT, Tan PH, Dheen ST, Duan W, Bay BH: Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis. 2002, 23: 81-86. 10.1093/carcin/23.1.81.View ArticlePubMedGoogle Scholar
- Kim HG, Kim JY, Han EH, Hwang YP, Choi JH, Park BH, Jeong HG: Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast cancer cells. FEBS Lett. 2011, 585: 421-428. 10.1016/j.febslet.2010.12.030.View ArticlePubMedGoogle Scholar
- Lim D, Jocelyn KM, Yip GW, Bay BH: Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells. Canc Lett. 2009, 276: 109-117. 10.1016/j.canlet.2008.10.038.View ArticleGoogle Scholar
- Rao PS, Jaggi M, Smith DJ, Hemstreet GP, Balaji KC: Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer. Biochem Biophys Res Commun. 2003, 310: 1032-1038. 10.1016/j.bbrc.2003.09.118.View ArticlePubMedGoogle Scholar
- Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO, Kim JH, Song KS, Rho SM, Yoo HS, Kim YS: Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Canc Res. 2005, 11: 473-482.Google Scholar
- Tuccari G, Giuffre G, Arena F, Barresi G: Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa. Histol Histopathol. 2000, 15: 1035-1041.PubMedGoogle Scholar
- Janssen AM, van Duijn W, Kubben FJ, Griffioen G, Lamers CB, van Krieken JH, van de Velde CJ, Verspaget HW: Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Canc Res. 2002, 8: 1889-1896.Google Scholar
- Ebert MP, Gunther T, Hoffmann J, Yu J, Miehlke S, Schulz HU, Roessner A, Korc M, Malfertheiner P: Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Canc Res. 2000, 60: 1995-2001.Google Scholar
- Ke Y, Ning T, Wang B: [Establishment and characterization of a SV40 transformed human fetal gastric epithelial cell line-GES-1]. Zhonghua Zhong Liu Za Zhi. 1994, 16: 7-10.PubMedGoogle Scholar
- Abdel-Mageed AB, Agrawal KC: Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. Canc Res. 1998, 58: 2335-2338.Google Scholar
- Yao J, Duan L, Fan M, Wu X: NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. Pharmacol Res. 2006, 54: 406-413. 10.1016/j.phrs.2006.08.003.View ArticlePubMedGoogle Scholar
- Manna SK, Bose JS, Gangan V, Raviprakash N, Navaneetha T, Raghavendra PB, Babajan B, Kumar CS, Jain SK: Novel derivative of benzofuran induces cell death mostly by G2/M cell cycle arrest through p53-dependent pathway but partially by inhibition of NF-kappaB. J Biol Chem. 2010, 285: 22318-22327. 10.1074/jbc.M110.131797.PubMed CentralView ArticlePubMedGoogle Scholar
- Du HP, Shen JK, Yang M, Wang YQ, Yuan XQ, Ma QL, Jin J: 4-Chlorobenzoyl berbamine induces apoptosis and G2/M cell cycle arrest through the PI3K/Akt and NF-kappaB signal pathway in lymphoma cells. Oncol Rep. 2010, 23: 709-716.PubMedGoogle Scholar
- Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Canc. 2011, 11: 558-572.View ArticleGoogle Scholar
- Kishimoto I, Mitomi H, Ohkura Y, Kanazawa H, Fukui N, Watanabe M: Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas. J Surg Oncol. 2008, 98: 60-66. 10.1002/jso.21087.View ArticlePubMedGoogle Scholar
- DiDonato JA, Mercurio F, Karin M: NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012, 246: 379-400. 10.1111/j.1600-065X.2012.01099.x.View ArticlePubMedGoogle Scholar
- Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5: 749-759. 10.1038/nri1703.View ArticlePubMedGoogle Scholar
- Inoue K, Takano H, Shimada A, Wada E, Yanagisawa R, Sakurai M, Satoh M, Yoshikawa T: Role of metallothionein in coagulatory disturbance and systemic inflammation induced by lipopolysaccharide in mice. FASEB J. 2006, 20: 533-535.PubMedGoogle Scholar
- Liu AL, Zhang ZM, Zhu BF, Liao ZH, Liu Z: Metallothionein protects bone marrow stromal cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation. Cell Biol Int. 2004, 28: 905-911. 10.1016/j.cellbi.2004.09.004.View ArticlePubMedGoogle Scholar
- Takano H, Inoue K, Yanagisawa R, Sato M, Shimada A, Morita T, Sawada M, Nakamura K, Sanbongi C, Yoshikawa T: Protective role of metallothionein in acute lung injury induced by bacterial endotoxin. Thorax. 2004, 59: 1057-1062. 10.1136/thx.2004.024232.PubMed CentralView ArticlePubMedGoogle Scholar
- Tao X, Zheng JM, Xu AM, Chen XF, Zhang SH: Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res. 2007, 37: 820-827. 10.1111/j.1872-034X.2007.00113.x.View ArticlePubMedGoogle Scholar
- Yan DW, Fan JW, Yu ZH, Li MX, Wen YG, Li DW, Zhou CZ, Wang XL, Wang Q, Tang HM, Peng ZH: Downregulation of metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue. Biochim Biophys Acta. 1822, 2012: 918-926.Google Scholar
- Duncan EL, Reddel RR: Downregulation of metallothionein-IIA expression occurs at immortalization. Oncogene. 1999, 18: 897-903. 10.1038/sj.onc.1202370.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.